89bio (ETNB) Competitors $5.78 -1.08 (-15.67%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETNB vs. PTCT, ZLAB, OGN, ACLX, RNA, RARE, RYTM, SWTX, AKRO, and CRNXShould you be buying 89bio stock or one of its competitors? The main competitors of 89bio include PTC Therapeutics (PTCT), Zai Lab (ZLAB), Organon & Co. (OGN), Arcellx (ACLX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Rhythm Pharmaceuticals (RYTM), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. 89bio vs. PTC Therapeutics Zai Lab Organon & Co. Arcellx Avidity Biosciences Ultragenyx Pharmaceutical Rhythm Pharmaceuticals SpringWorks Therapeutics Akero Therapeutics Crinetics Pharmaceuticals 89bio (NASDAQ:ETNB) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Which has stronger valuation & earnings, ETNB or PTCT? 89bio has higher earnings, but lower revenue than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89bioN/AN/A-$142.19M-$3.43-1.75PTC Therapeutics$806.78M4.22-$626.60M-$4.73-9.13 Do analysts prefer ETNB or PTCT? 89bio currently has a consensus target price of $27.56, suggesting a potential upside of 359.26%. PTC Therapeutics has a consensus target price of $63.77, suggesting a potential upside of 47.61%. Given 89bio's stronger consensus rating and higher possible upside, research analysts clearly believe 89bio is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89bio 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90PTC Therapeutics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53 Is ETNB or PTCT more profitable? 89bio has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat 89bio's return on equity.Company Net Margins Return on Equity Return on Assets 89bioN/A -59.58% -52.21% PTC Therapeutics -50.32%N/A -16.44% Does the media refer more to ETNB or PTCT? In the previous week, PTC Therapeutics had 7 more articles in the media than 89bio. MarketBeat recorded 13 mentions for PTC Therapeutics and 6 mentions for 89bio. 89bio's average media sentiment score of 0.75 beat PTC Therapeutics' score of 0.65 indicating that 89bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 89bio 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ETNB or PTCT? PTC Therapeutics received 455 more outperform votes than 89bio when rated by MarketBeat users. However, 63.33% of users gave 89bio an outperform vote while only 61.92% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperform89bioOutperform Votes11463.33% Underperform Votes6636.67% PTC TherapeuticsOutperform Votes56961.92% Underperform Votes35038.08% Which has more risk & volatility, ETNB or PTCT? 89bio has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Summary89bio beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks. Remove Ads Get 89bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETNB vs. The Competition Export to ExcelMetric89bioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$876.63M$6.43B$5.33B$7.13BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-2.066.8022.8917.40Price / SalesN/A188.30357.5184.53Price / CashN/A65.6738.1634.64Price / Book1.045.636.253.79Net Income-$142.19M$142.11M$3.21B$247.10M7 Day Performance-25.74%-11.37%-8.04%-7.61%1 Month Performance-29.25%-14.47%-2.99%-10.32%1 Year Performance-43.66%-18.40%3.54%-7.75% 89bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETNB89bio2.9099 of 5 stars$5.79-15.7%$27.56+376.3%-36.9%$839.99MN/A-1.9840Gap DownPTCTPTC Therapeutics3.7379 of 5 stars$50.96-6.0%$63.77+25.1%+61.1%$4.02B$806.78M-8.581,410Gap DownHigh Trading VolumeZLABZai Lab2.2979 of 5 stars$36.14-3.1%$47.37+31.1%+130.8%$3.96B$398.99M-13.051,950Insider TradeNews CoverageGap DownOGNOrganon & Co.4.7014 of 5 stars$14.92+2.8%$20.80+39.4%-19.5%$3.85B$6.40B4.4810,000Positive NewsGap DownACLXArcellx1.985 of 5 stars$65.60-3.5%$108.46+65.3%-1.2%$3.60B$107.94M-92.3980News CoveragePositive NewsGap DownRNAAvidity Biosciences2.4824 of 5 stars$29.52-6.6%$66.69+125.9%+5.5%$3.55B$10.90M-10.25190Insider TradeGap DownHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3379 of 5 stars$36.21-4.3%$92.79+156.2%-25.4%$3.35B$560.23M-5.711,310News CoveragePositive NewsGap DownRYTMRhythm Pharmaceuticals4.3773 of 5 stars$52.97-3.3%$69.46+31.1%+21.8%$3.35B$130.13M-12.23140Gap DownSWTXSpringWorks Therapeutics1.8947 of 5 stars$44.13-6.9%$73.20+65.9%-6.8%$3.31B$191.59M-12.68230Positive NewsGap DownAKROAkero Therapeutics4.0628 of 5 stars$40.48-5.2%$76.29+88.5%+72.5%$3.22BN/A-10.7930Gap DownCRNXCrinetics Pharmaceuticals4.3137 of 5 stars$33.54-3.4%$73.00+117.7%-39.4%$3.12B$1.04M-8.99210News CoveragePositive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies PTC Therapeutics Alternatives Zai Lab Alternatives Organon & Co. Alternatives Arcellx Alternatives Avidity Biosciences Alternatives Ultragenyx Pharmaceutical Alternatives Rhythm Pharmaceuticals Alternatives SpringWorks Therapeutics Alternatives Akero Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETNB) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 89bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ETNB Stock Free ETNB Stock Alerts